Optimapharm
Optimapharm has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €97k and a net result of €92k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 33% of 2244 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
| Equity | €97k |
| Net result | €92k |
| Staff (FTE) | 1 |
| Better than sector | 33% |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 38.8% | 59.8% | |
| Net result | €92k | €121k | |
| Equity | €97k | €395k | |
| Gross operating margin | €386k | €301k | |
| Staff costs | €257k | €111k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | €128k | €16k | €35k | €7k |
| Net profit | €92k | €11k | €25k | €3k |
| Cash flow | €94k | €11k | €26k | €3k |
| Staff costs | €257k | €231k | €179k | €27k |
| Income taxes | €34k | €4k | €865 | €-9 |
| Dividends | - | - | - | - |
| Total assets | €249k | €102k | €92k | €147k |
| Equity | €97k | €5k | €-6k | €-31k |
| Debt | €153k | €97k | €98k | €178k |
| of which ≤ 1y | €153k | €97k | €98k | €178k |
| of which > 1y | - | - | - | - |
| Working capital | €90k | €5k | €-6k | €-32k |
| Employees (FTE) | 1.0 | 1.0 | 0.8 | 0.2 |
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 1.59 | 1.05 | 0.94 | 0.82 |
| Quick ratio | 1.59 | 1.05 | 0.94 | 0.82 |
| Working capital ratio | 36.2% | 4.5% | -6.8% | -21.8% |
| Solvency | 38.8% | 4.5% | -6.7% | -21.4% |
| Debt / equity | 1.58 | 21.11 | -16.02 | -5.68 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 122.30 | 38.07 | 4.36 | 1.73 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 36.9% | 10.6% | 27.4% | 1.8% |
| ROE | 95.2% | 233.4% | -410.8% | -8.4% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Full annual accounts (22 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €249k | €102k | €92k | €147k |
| Fixed assets | 21/28 | €6k | - | €155 | €664 |
| Tangible fixed assets | 22/27 | €6k | - | €155 | €664 |
| Current assets | 29/58 | €243k | €102k | €92k | €146k |
| Amounts receivable within one year | 40/41 | €202k | €86k | €66k | €129k |
| Cash & bank | 54/58 | €40k | €16k | €26k | €16k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €249k | €102k | €92k | €147k |
| Equity | 10/15 | €97k | €5k | €-6k | €-31k |
| Contributions / capital | 10/11 | €19k | €19k | €19k | €19k |
| Reserves | 13 | - | - | - | €89 |
| Accumulated profits (losses) | 14 | €78k | €-14k | €-25k | €-50k |
| Amounts payable | 17/49 | €153k | €97k | €98k | €178k |
| Amounts payable within one year | 42/48 | €153k | €97k | €98k | €178k |
| Trade debts payable within one year | 44 | €17k | €2k | €15k | €537 |
| Income statement | |||||
| Gross operating margin | 9900 | €386k | €247k | €214k | €35k |
| Operating result | 9901 | €126k | €15k | €34k | €7k |
| Financial income | 75 | €342 | €0 | - | - |
| Financial charges | 65 | €1k | €409 | €8k | €4k |
| Result before taxes | 9903 | €126k | €15k | €26k | €3k |
| Income taxes | 67/77 | €34k | €4k | €865 | €-9 |
| Net result for the period | 9904 | €92k | €11k | €25k | €3k |
| Result to be appropriated | 9905 | €92k | €11k | €25k | €3k |
-
Mirna Šenjug NovakDirectorState Gazette act 24039976 (06-03-2024)Current23-11-2023 → present
Former directors (1)
-
Martina Okun ŠolaDirectorState Gazette act 24039976 (06-03-2024)Former- → 23-11-2023
| NACE primary | Medical imaging and medical laboratories(86910) |
| Legal form | Private limited company(610) |
| Incorporation | 17-08-2015 |
| Status | Active |
| Postal code | 9220 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 42452C0148/00L000 | Flanders | 2,493 m² | 1 · 591 m² | 7.7 m · 2 fl. |
We know of 7 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
06-03-2024 1 director appointed, 1 resigning
- Mirna Šenjug Novak, Bestuurder
- Martina Okun Šola, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Martina Okun \u0160ola",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "voluntary",
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2023-11-23",
"evidence_quote": "De algemene vergadering neemt kennis van het vrijwillig ontslag van mevrouw Martina Okun \u0160ola, ingang nemende op 23 november 2023. Er wordt mevrouw Martina Okun \u0160ola kwijting verleend.",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mirna \u0160enjug Novak",
"address": "Ulica Otona Ku\u010Dere 15, Zagreb 10000, Kroati\u00EB",
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": "2023-11-23",
"evidence_quote": "De algemene vergadering stelt vervolgens aan als bestuurder voor onbepaalde duur en ingang nemend op 23 november 2023: - mevrouw Mirna \u0160enjug Novak, wonende te Ulica Otona Ku\u010Dere 15, Zagreb 10000, Kroati\u00EB.",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Gent",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-03-06",
"filing_date": "2024-02-26",
"act_kind_objet": "Onderwerp akte:"
},
"decisions": [
{
"body": "algemene_vergadering",
"date": "2023-11-23",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0635.584.382",
"name_full": "Optimapharm",
"legal_form": "BV"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Ivana Waller",
"org_rep_person_name": null,
"person_role_at_subject": "bestuurder"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}| Legal nameNL | Optimapharm |